AbbVie (ABBV) and Gubra A/S announced a license agreement to develop GUB014295, a potential long-acting amylin analog for the treatment of obesity. AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales. GUB014295 is currently in a Phase 1 clinical trial.
Gubra, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com